文献速递肝病

FXR激动剂在NASH治疗中的应用

FXR agonists in NASH treatment.
PubMed 文献 · J Hepatol · 2023-08-09

本文综述法尼醇X受体(FXR)在非酒精性脂肪性肝炎(NASH)中的作用机制及最具临床进展的FXR激动剂的临床前与临床特征,并批判性评估其在NASH治疗中的潜力;NASH尚缺乏获批药物,FXR激活已成为确立的药理靶点。

要点

  • FXR是胆汁酸激活的核受体,调控胆固醇与胆汁酸稳态、糖异生、脂质合成、炎症和纤维化。
  • NASH以肝脂肪变、肝细胞损伤(气球样变)和炎症为特征,可进展为纤维化、肝硬化和肝细胞癌。
  • 多种FXR激动剂(胆汁酸衍生物、非胆汁酸甾体、非甾体及部分激动剂)处于晚期临床开发。

核心结论

  • FXR激活已成为NASH治疗中确立的药理靶点,多种FXR激动剂处于晚期临床开发,本综述批判性评估其治疗NASH的潜力。

研究设计与样本

  • 综述:总结最具临床进展的FXR激动剂的关键临床前与临床特征。

主要发现

  • FXR在肝和肠道高表达,调控胆固醇与胆汁酸稳态、肝糖异生、脂质合成、炎症和纤维化相关基因表达。
  • FXR还控制肠道屏障完整性、防止细菌易位并维持肠道菌群稳态。
  • NASH以肝脂肪变、肝细胞损伤(气球样变)和炎症为特征,可导致纤维化、肝硬化和肝细胞癌。

关键数值与推荐

  • FXR激动剂按理化性质 broadly 分为胆汁酸衍生物、非胆汁酸甾体FXR激动剂、非甾体FXR激动剂和部分FXR激动剂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The farnesoid X receptor (FXR), a bile acid (BA)-activated nuclear receptor highly expressed in the liver and intestine, regulates the expression of genes involved in cholesterol and bile acid homeostasis, hepatic gluconeogenesis, lipogenesis, inflammation and fibrosis, in addition to controlling intestinal barrier integrity, preventing bacterial translocation and maintaining gut microbiota eubiosis. Non-alcoholic steatohepatitis (NASH), an advanced stage of non-alcoholic fatty liver disease, is characterized by hepatic steatosis, hepatocyte damage (ballooning) and inflammation, leading to fibrosis, cirrhosis and hepatocellular carcinoma. NASH represents a major unmet medical need, but no pharmacological treatments have yet been approved. The pleiotropic mechanisms involved in NASH development offer a range of therapeutic opportunities and among them FXR activation has emerged as an established pharmacological target. Various FXR agonists with different physicochemical properties, which can be broadly classified as BA derivatives, non-BA-derived steroidal FXR agonists, non-steroidal FXR agonists, and partial FXR agonists, are in advanced clinical development. In this review we will summarize key preclinical and clinical features of the most advanced FXR agonists and critically evaluate their potential in NASH treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Adorini L, Trauner M. FXR agonists in NASH treatment. J Hepatol. 2023. PMID: 37562746. doi:10.1016/j.jhep.2023.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。